Clinical management of respiratory tract infections in the community: Experience with telithromycin

Infection

Volumn 29, Issue SUPPL. 2, 2001, Pages 16-22

  Quintiliani, R ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Acute exacerbations of chronic bronchitis; Community acquired pneumonia; Sinusitis; Telithromycin; Tonsillitis pharyngitis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; ERYTHROMYCIN; KETOLIDE; MACROLIDE; PENICILLIN G; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; ERADICATION THERAPY; HAEMOPHILUS INFLUENZAE; HUMAN; MORAXELLA CATARRHALIS; PATIENT COMPLIANCE; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RESPIRATORY TRACT INFECTION; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; TONSILLITIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS, PHASE III; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; KETOLIDES; MACROLIDES; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 0035662261     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Practice guidelines for the management of community-acquired pneumonia in adults
2. Prevalence of selected chronic conditions: United States 1986-1988
3. Pharyngitis
4. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity and initial antimicrobial therapy
5. IDCP guidelines: Management of upper respiratory tract infections
6. Treatment of community-acquired pneumonia - IDSA guidelines
7. Diagnosis and management of group A streptococcal pharyngitis: A practice guideline
8. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital
9. Management of acute exacerbation of chronic bronchitis
10. Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
11. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
12. Community-acquired pneumonia due to atypical organisms in adults: Diagnosis and treatment
13. Erythromycin resistance genes in group A streptococci of different geographical origins
14. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America
15. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: Contributions of type II topoisomerase mutations and efflux to levels of resistance
16. Emerging resistance problems among respiratory tract pathogens
17. Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: Identification of gyrA and parC and specification of point mutations associated with resistance
18. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains
19. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
20. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
21. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany
22. In vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and β-haemolytic streptococci
23. Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila
24. Activity of telithromycin (HMR 3647), a new ketolide antimicrobial, against human mycoplasmas
25. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia
26. In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at phs 6.8 and 7.4
27. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae
28. Susceptibilities of Legionella spp. to newer antimicrobials in vitro
29. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan
30. Comparative in vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status
31. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY antimicrobial surveillance program
32. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
33. Sinusitis: Bench to bedside: Current findings, future directions
34. Acute vs chronic sinusitis: Etiology, management, and outcomes
35. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: A fifteen-year experience at the University of Virginia and review of other selected studies
36. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute sinusitis
37. Telithromycin
38. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: A statement for health professionals
39. Efficacy of 5 days' telithromycin (HMR 3647) vs 10 days' penicillin V in the treatment of pharyngitis in adults
40. Oral telithromycin (HMR 3647) 800 mg once daily for 5 days and 10 days is well tolerated and as effective as oral clarithromycin 250 mg twice daily for 10 days in group A-hemolytic streptococcal (GABHS) pharyngitis/tonsillitis
41. Changing patterns of etiology and resistance in community-acquired respiratory tract infections
42. Acute pneumonia
43. Efficacy of telithromycin (HMR 3647), a new once-daily antimicrobial, in the treatment of community-acquired pneumonia
44. Efficacy and tolerability of telithromycin (HMR 3647) vs high-dose amoxicillin in the treatment of community-acquired pneumonia
45. Oral telithromycin (HMR 3647) 800 mg once daily is well tolerated and as effective as oral clarithromycin 500 mg twice daily in community-acquired pneumonia (CAP) in adults
46. Chronic bronchitis and acute infectious exacerbations
47. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
48. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute exacerbations of chronic bronchitis in patients with COPD